OS4.4 Hypofractionated stereotactic radiotherapy and anti-PDL1 Durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial

Por Pouessel, D, Mervoyer, A, Larrieu-Ciron, D, Cabarrou, B, Robert, M, Frenel, J, Olivier, P, Mounier, M, Cohen-Jonathan Moyal, E
Publicado no Neuro Oncol (2019)

P20.01 MEVITEM: A European, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or ref...

Por Frappaz, D., Meyronnet, D., Garin, G., Laigle-Donadey, F., Le Rhun, E., Bonneville-Levard, A., Frenel, J., Idbaih, A., Gourmelon, C., Chinot, O.
Publicado no Neuro Oncol (2016)

Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas

Por Loussouarn, D, Campion, L, Sagan, C, Frenel, J-S, Dravet, F, Classe, J-M, Pioud-Martigny, R, Berton-Rigaud, D, Bourbouloux, E, Mosnier, J-F, Bataille, F-R, Campone, M
Publicado em 2008

P04.12 Characteristics of IDH-mutant gliomas with non-canonical IDH mutations

Por Poetsch, L, Dehais, C, Frénel, J, Siegfried, A, Lacomme, S, Seizeur, R, Larrieu-Ciron, D, Cappellen, D, Loussouarn, D, Ferec, C, Eimer, S, Carpentier, C, Sanson, M, Delattre, J, Figarella-Branger, D, Ducray, F, Bronnimann, C
Publicado no Neuro Oncol (2019)

P11.08 Defining EGFR amplification status for clinical trial inclusion

Por French, P, Eoli, M, Sepulveda, J, de Heer, I, Kros, J M, Walenkamp, A, Frenel, J, Franceschi, E, Clement, P, Weller, M, Ansell, P, Looman, J, Bain, E, Morfouace, M, Gorlia, T, van den Bent, M
Publicado no Neuro Oncol (2019)

OS4.3 Feasibility and benefit of Molecular Profiling to Guide Enrollment of Patients with Recurrent Gliomas in Early Phase Trials

Por Baldini, C, Younan, N, Castanon Alvarez, E, Bahleda, R, Hollebecque, A, Dhermain, F, Ammari, S, Alentorn, A, Dumont, S, Frenel, J, Di Stefano, A, Bielle, F, Hoang-Xuan, K, Delattre, J, Soria, J, Sanson, M, Idbaih, A, Massard, C, Touat, M
Publicado no Neuro Oncol (2019)